INTEGRATED FILING — Other than Banks



General information about company

Scrip code 000000
NSE Symbol SANGANI
MSEI Symbol NOTLISTED
ISIN INE0OVI01010
Name of Company SANGANI HOSPITALS LIMITED
Type of company SME
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 30-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 21-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment HEALTHCARE
Start date and time of board meeting 30-May-2025   12:00:00
End date and time of board meeting 30-May-2025   23:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion


Financial Results — Other than Bank

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Revenue From Operations
Revenue from operations 111769000 211852000
Other income 8468000 16066000
Total Income 120237000 227918000
2 Expenses
(a) Cost of materials consumed 55566000 101333000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 185000 -3514000
(d) Employee benefit expense 21385000 40167000
(e) Finance costs 0 0
(f) Depreciation and amortisation expense 4247000 5955000
(g) Other Expenses
1 other 27035000 49360000
Total other expenses 27035000 49360000
Total expenses 108418000 193301000
3 Profit before exceptional and extraordinary items and tax 11819000 34617000
4 Exceptional items 0 0
5 Profit before extraordinary items and tax 11819000 34617000
6 Extraordinary items 0 0
7 Profit before tax 11819000 34617000
8 Tax Expense
Current tax 2415000 6910000
Deferred tax 544000 1769000
Total tax expenses 2959000 8679000
9 Net Profit Loss for the period from continuing operations 8860000 25938000
10 Profit (loss) from discontinuing operations before tax 0 0
11 Tax expense of discontinuing operations 0 0
12 Net profit (loss) from discontinuing operation after tax 0 0
13 Profit (loss) for period before minority interest 8860000 25938000
14 Share of profit (loss) of associates 0 0
15 Profit (loss) of minority interest 0 0
16 Net profit (Loss) for the period 8860000 25938000
17 Details of equity share capital
Paid-up equity share capital 137770000 137770000
Face value of equity share capital 10 10
18 Reserves excluding revaluation reserve 0
19 Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.64 1.88
Diluted earnings (loss) per share from continuing and discontinued operations 0.64 1.88
20 Debt equity ratio 0.0 0.0
21 Debt service coverage ratio 0.0 0.0
22 Interest service coverage ratio 0.0 0.0
23 Disclosure of notes on financial results Textual Information(1)


Text Block

Textual Information(1) Notes: 1.The above results were reviewed and recommended by the Audit Committee, at its meeting held on May 30,2025, for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The above result is subjected to Limited Review by the Statutory Auditors of the Company, as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. These results have been prepared in accordance with the recognition and measurement principles laid down in AS-25 Interim Financials Reporting presribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued thereunder and other accounting principles generally accepted in India. 3. The figures for the half year ended on 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year 2024-25 and the half year ended unaudited figures upto 30th September, 2024 4. The Company is engaged in the business of healthcare related services. In the management opinion, this is the only segment and hence there are no separate reportable segment as per AS-17 on Segement Reporting. 5. The Compnay has completed its Initial Public Offering ( IPO ) of 37,92,000 new Equity Shares of Rs. 10 each at premium of Rs. 30 each per Equity Shares aggregating to Rs. 1516.80 lakhs. Pursuant to the IPO, the Equity Shares of the Company have got listed on NSE Emerge Platform on August 17, 2023. 6. The above consolidated financial result include the result of Subsidiary firm; M/s. Ankur Distributors 7. The above financial results are available on the website of the company i.e. www.sanganihospitals.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com 8.Figures for previous half year/ year have been regrouped wherever necessary to make them comparable.


Remarks

20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio


Cash flow statement — indirect

A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
1 Statement of cash flows
Cash flows from used in operating activities
Profit before extraordinary items and tax 34617000
2 Adjustments for reconcile profit (loss)
Adjustments to profit (loss)
Adjustments for finance costs 0
Adjustments for depreciation and amortisation expense 5955000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for share-based payments 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments to profit (loss) 5955000
3 Adjustments for working capital
Adjustments for decrease (increase) in inventories -3514000
Adjustments for decrease (increase) in trade receivables -6964000
Adjustments for decrease (increase) in other current assets -9125000
Adjustments for increase (decrease) in trade payables -312000
Adjustments for increase (decrease) in other current liabilities 8911000
Adjustments for provisions 799000
Total adjustments for working capital -10205000
Total adjustments for reconcile profit (loss) -4250000
Net cash flows from (used in) operations 30367000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 6910000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities before extraordinary items 23457000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) operating activities 23457000
4 Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property plant and equipment 0
Purchase of property plant and equipment 10917000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Proceeds from government grants 0
Net cash flows from (used in) investing activities before extraordinary items -10917000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) investing activities -10917000
Cash flows from used in financing activities
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Dividends paid 0
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash -22574000
Net cash flows from (used in) financing activities before extraordinary items -22574000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) financing activities -22574000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -10034000
6 Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -10034000
Cash and cash equivalents cash flow statement at beginning of period 191704000
Cash and cash equivalents cash flow statement at end of period 181670000


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Equity and liabilities
1 Shareholders' funds
Share capital 137770000
Reserves and surplus 223087000
Money received against share warrants 0
Total shareholders' funds 360857000
2 Share application money pending allotment 0
3 Deferred government grants 0
4 Minority interest 293000
5 Non-current liabilities
Long-term borrowings 853000
Deferred tax liabilities (net) 4716000
Foreign currency monetary item translation difference liability account 0
Other long-term liabilities 0
Long-term provisions 907000
Total non-current liabilities 6476000
6 Current liabilities
Short-term borrowings 0
Trade Payables
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 10174000
Total Trade payable 10174000
Other current liabilities 13130000
Short-term provisions 875000
Total current liabilities 24179000
Total equity and liabilities 391805000
Assets
1 Non-current assets
i Property, Plant and Equipment and Intangible assets
Property, Plant and Equipment 131767000
Producing properties 0
Intangible assets 0
Preproducing properties 0
Property, Plant and Equipment capital work-in-progress 0
Intangible assets under development or work-in-progress 0
Total Property, Plant and Equipment and Intangible assets 131767000
ii Non-current investments 0
v Deferred tax assets (net) 0
vi Foreign currency monetary item translation difference asset account 0
vii Long-term loans and advances 27463000
viii Other non-current assets 0
Total non-current assets 159230000
Current assets
Current investments 0
Inventories 11252000
Trade receivables 29483000
Cash and cash equivalents 0
Bank balance other than cash and cash equivalents 181670000
Short-term loans and advances 0
Other current assets 10170000
Total current assets 232575000
Total assets 391805000
Disclosure of notes on assets and liabilities


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Oct-2024 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets
Net Segment Asset
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities
Net Segment Liabilities
Disclosure of notes on segments




Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 KUMBHAT & COMPANY Yes 30-Sep-2026